Chemical formula: C₁₉H₂₇N₅O₄ Molecular mass: 389.449 g/mol PubChem compound: 2092
Alfuzosin is an orally active quinazoline derivative. It is a selective, peripherally acting antagonist of postsynaptic alpha-1-adrenoceptors. In vitro pharmacological studies have documented the selectivity of alfuzosin for the alpha-1-adrenoreceptors located in the prostate, bladder base and prostatic urethra.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| G04CA01 | Alfuzosin | G Genito urinary system and sex hormones → G04 Urologicals → G04C Drugs used in benign prostatic hypertrophy → G04CA Alpha-adrenoreceptor antagonists |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| XATRAL XL Prolonged release tablets | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Alfuzosin is an active ingredient of these brands:
United States (US)
Australia (AU)
Austria (AT)
Brazil (BR)
Canada (CA)
Ecuador (EC)
Estonia (EE)
Finland (FI)
Germany (DE)
Hong Kong (HK)Italy (IT)Lithuania (LT)
Malta (MT)Mexico (MX)
Netherlands (NL)
Nigeria (NG)
Poland (PL)Singapore (SG)
Spain (ES)
Turkey (TR)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
